Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can psychotherapy extend Ketamine's pain relief? small study hopes to find out

NCT ID NCT05639322

Symptom relief Sponsor: Unity Health Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether adding cognitive behavioral therapy and mindfulness meditation to ketamine infusions could make pain relief last longer for people with chronic nerve pain. Thirty adults with moderate-to-severe neuropathic pain were randomly assigned to receive ketamine alone, therapy alone, or both together. The main goal was to see if the combined approach is feasible and safe, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketamine hydrochloride (an anesthetic drug) and cognitive behavioral therapy/mindfulness meditation
What this could lead to
If successful, this could point toward a longer-lasting treatment for chronic nerve pain without needing frequent repeat infusions.
What could go wrong
This is a very small pilot study (30 people) focused on feasibility, not proof of effectiveness. Results may not apply to everyone with neuropathic pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Started

Oct 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years of age 2. Diagnosis of chronic neuropathic pain as determined by a pain specialist with moderate-to-severe neuropathic pain as per ID pain questionnaire, with mean pain scores \> 3 on a numeric rating scale (NRS), in the 7 days preceding inclusion 3. For participants of childbearing potential, use highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the participant 4. Capacity to provide informed consent Exclusion Criteria: 1. Patients less than 18 years of age 2. Current or lifetime history of schizophrenia, psychotic disorder, bipolar disorder, or borderline personality disorder 3. Known history of hypersensitivity or allergy to Ketamine-HCL 4. Current history of dissociative disorders 5. Current concomitant use of theophylline or aminophylline 6. Current elevated intracranial pressure 7. Pregnancy or ongoing breastfeeding in female participants 8. Concomitant active substance use in the 6 months preceding enrolment (amphetamines, alcohol, and ketamine) 9. Contraindication to receiving Ketamine-HCL (e.g. current or lifetime history of cerebrovascular accident; current significant hypertension \[systolic blood pressure higher than 160 mmHg and/or diastolic blood pressure higher than 100 mmHg\]; current severe cardiac decompensation \[e.g. presence of dyspnea, peripheral edema, elevated jugular venous pressure, hepatomegaly, pulmonary rales, pleural effusions\])

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuropathic pain are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuropathic pain

Contacts and locations

Locations

  • St. Michael's Hospital

    Toronto, Ontario, M5B 1W8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.